Additional duplicate genetic tests prevented by the BPA included FMR1 (fragile X mutation analysis, n = 9), cystic fibrosis mutation analysis (n = 4), and SMN1 (spinal muscular atrophy,n = 2), along with five additional tests that were prevented one time each (CYP21A2, FBN1, MEN1, RET, SCN1A gene sequencing panels). This evidence concerns the gene FBN1 and spinal muscular atrophy.